SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 317.29 |
| Enterprise Value ($M) | 749.99 |
| Book Value ($M) | 582.91 |
| Book Value / Share | 20.85 |
| Price / Book | 0.54 |
| NCAV ($M) | -339.62 |
| NCAV / Share | -12.15 |
| Price / NCAV | -0.93 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.17 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.97 |
| Current Ratio | 2.02 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 588.26 |
| Assets | 1,510.79 |
| Liabilities | 927.89 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,738.69 |
| Operating Income | -85.23 |
| Net Income | -266.41 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -53.41 |
| Cash from Investing | -78.64 |
| Cash from Financing | 131.47 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ameriprise Financial Inc | 7.62 | 29.33 | |
| 13G/A | Vanguard Group Inc | 5.64 | 0.00 | |
| 13G/A | Dimensional Fund Advisors Lp | 6.60 | -18.92 | |
| 13G/A | BlackRock, Inc. | 12.10 | 13.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 33,057 | 196,234 | 16.85 | |
| 47,597 | 275,657 | 17.27 | |
| 61,993 | 368,163 | 16.84 | |
| 81,902 | 537,655 | 15.23 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QNCX – Quince Therapeutics, Inc. | QURE – uniQure N.V. |
| RARE – Ultragenyx Pharmaceutical Inc. | REGN – Regeneron Pharmaceuticals, Inc. |
| REPL – Replimune Group, Inc. |